GlaxoSmithKline is looking for opportunities in oncology
Collaboration with others in industry, academia, government and non-governmental organisations and healthcare in general is fundamental to GSK's strategic priorities of growing a diversified, global business and delivering more products of value.
Their Worldwide Business Development group is a global team of scientific, transaction, and alliance management experts building diverse collaborations relating to compounds (early stage discovery programs through to marketed products) and technologies. If you prefer to retain the independence to develop alliance compounds through to proof of concept, their Options based collaborative model offers you the flexibility for you to do so. They have an industry leading record in establishing and maintaining collaborations with scientists and organizations in both industry and academia and are experts at building progressive relationships that are strong and mutually beneficial.
Priority areas of science
They are strongly committed to research collaborations with academic groups to advance scientific understanding relevant to their key areas of focus:
- Metabolic pathways
- Infectious diseases
Specific topics of interest currently for academic collaboration are outlined below.
- Tumor metabolism
- Cancer stem cell pathways
- The epithelial-mesenchymal transition
- Oncology targets for Biopharmaceuticals
- Linkage of early oncology discovery activities with clinically meaningful endpoints (e.g. via biomarkers, bioimaging)
- Health outcomes and reimbursement/access research
- Bioinformatics, study designs and adaptive design modelling
- Optimizing data collection and management
- Tools for investigator training and improving study outcomes